GH Dec 2023 55.000 call
| Previous close | 17.80 |
| Open | 1.4000 |
| Bid | 0.6500 |
| Ask | 1.3000 |
| Strike | 55.00 |
| Expiry date | 2023-12-15 |
| Day's range | 17.80 - 17.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 140 |
- Business Wire
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
PALO ALTO, Calif., March 21, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced support for an investigator initiated study led and conducted by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) to evaluate patient compliance with a blood-based test for colorectal cancer (CRC) screening. In this study, The Ohio State University Guardant Shield Colorectal Canc
- Simply Wall St.
In the wake of Guardant Health, Inc.'s (NASDAQ:GH) latest US$536m market cap drop, institutional owners may be forced to take severe actions
Key Insights Institutions' substantial holdings in Guardant Health implies that they have significant influence over...
- Business Wire
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
PALO ALTO, Calif., March 10, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval (PMA) application for Shield™, Guardant Health’s blood test to screen for colorectal cancer (CRC).
